Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products
Jupiter Neurosciences (NASDAQ: JUNS) has announced a strategic partnership with Aquanova AG to develop consumer nutritional products focused on longevity, aging, and healthspan. The collaboration builds on their 8-year partnership in developing JOTROL™, Jupiter's resveratrol-based platform currently advancing to Phase IIa trials for Parkinson's Disease.
The companies will launch three consumer products in Q3 2025 through a Direct-to-Consumer model, focusing on 'Beauty from Within' concepts. These products will be marketed through a new wholly owned Jupiter subsidiary, allowing existing shareholders to participate in the commercial venture while generating revenue to support ongoing pharmaceutical trials.
The partnership leverages Aquanova's NovaSOL™ technology to address resveratrol's bioavailability challenges, ensuring effective absorption without GI side effects. This initiative represents both a strategic business expansion and a response to consumer demand for science-backed longevity solutions.
Jupiter Neurosciences (NASDAQ: JUNS) ha annunciato una partnership strategica con Aquanova AG per sviluppare prodotti nutrizionali per i consumatori focalizzati sulla longevità, l'invecchiamento e la salute. La collaborazione si basa sulla loro partnership di 8 anni nello sviluppo di JOTROL™, la piattaforma a base di resveratrolo di Jupiter, attualmente in fase di avanzamento verso le sperimentazioni di Fase IIa per il Morbo di Parkinson.
Le aziende lanceranno tre prodotti per i consumatori nel Q3 2025 attraverso un modello Direct-to-Consumer, concentrandosi sui concetti di 'Bellezza dall'Interno'. Questi prodotti saranno commercializzati tramite una nuova sussidiaria interamente posseduta da Jupiter, consentendo agli azionisti esistenti di partecipare all'iniziativa commerciale generando al contempo entrate per sostenere le sperimentazioni farmaceutiche in corso.
La partnership sfrutta la tecnologia NovaSOL™ di Aquanova per affrontare le sfide della biodisponibilità del resveratrolo, garantendo un'assorbimento efficace senza effetti collaterali gastrointestinali. Questa iniziativa rappresenta sia un'espansione strategica dell'attività sia una risposta alla domanda dei consumatori per soluzioni di longevità supportate dalla scienza.
Jupiter Neurosciences (NASDAQ: JUNS) ha anunciado una asociación estratégica con Aquanova AG para desarrollar productos nutricionales para consumidores enfocados en la longevidad, el envejecimiento y la salud. La colaboración se basa en su asociación de 8 años en el desarrollo de JOTROL™, la plataforma de Jupiter basada en resveratrol que actualmente avanza hacia ensayos de Fase IIa para la enfermedad de Parkinson.
Las empresas lanzarán tres productos para consumidores en Q3 2025 a través de un modelo Direct-to-Consumer, centrándose en conceptos de 'Belleza desde Dentro'. Estos productos se comercializarán a través de una nueva subsidiaria de propiedad total de Jupiter, permitiendo a los accionistas existentes participar en la aventura comercial mientras generan ingresos para apoyar los ensayos farmacéuticos en curso.
La asociación aprovecha la tecnología NovaSOL™ de Aquanova para abordar los desafíos de biodisponibilidad del resveratrol, asegurando una absorción efectiva sin efectos secundarios gastrointestinales. Esta iniciativa representa tanto una expansión estratégica del negocio como una respuesta a la demanda de los consumidores de soluciones de longevidad respaldadas por la ciencia.
주피터 뉴로사이언스 (NASDAQ: JUNS)는 아쿠아노바 AG와 전략적 파트너십을 발표하여 장수, 노화 및 건강 수명을 중심으로 한 소비자 영양 제품을 개발합니다. 이 협력은 파킨슨병을 위한 2a상 임상 시험으로 진행 중인 주피터의 레스베라트롤 기반 플랫폼인 JOTROL™ 개발을 위한 8년 파트너십에 기반하고 있습니다.
이들 회사는 2025년 3분기에 '내부의 아름다움' 개념에 중점을 두고 소비자 제품 3종을 직접 소비자 모델을 통해 출시할 예정입니다. 이 제품들은 주피터의 새로운 완전 자회사 통해 마케팅될 것이며, 기존 주주들이 상업적 벤처에 참여하고 지속적인 제약 시험을 지원하기 위한 수익을 창출할 수 있게 합니다.
이 파트너십은 아쿠아노바의 NovaSOL™ 기술을 활용하여 레스베라트롤의 생체이용률 문제를 해결하고, 위장 부작용 없이 효과적인 흡수를 보장합니다. 이 이니셔티브는 전략적 사업 확장과 과학에 기반한 장수 솔루션에 대한 소비자 수요에 대한 응답을 모두 나타냅니다.
Jupiter Neurosciences (NASDAQ: JUNS) a annoncé un partenariat stratégique avec Aquanova AG pour développer des produits nutritionnels destinés aux consommateurs, axés sur la longévité, le vieillissement et la santé. La collaboration s'appuie sur leur partenariat de 8 ans dans le développement de JOTROL™, la plateforme à base de resvératrol de Jupiter, actuellement en phase IIa d'essais pour la maladie de Parkinson.
Les entreprises lanceront trois produits destinés aux consommateurs au Q3 2025 via un modèle Direct-to-Consumer, en se concentrant sur des concepts de 'Beauté de l'Intérieur'. Ces produits seront commercialisés par le biais d'une nouvelle filiale entièrement détenue par Jupiter, permettant aux actionnaires existants de participer à l'entreprise commerciale tout en générant des revenus pour soutenir les essais pharmaceutiques en cours.
Le partenariat exploite la technologie NovaSOL™ d'Aquanova pour relever les défis de la biodisponibilité du resvératrol, garantissant une absorption efficace sans effets secondaires gastro-intestinaux. Cette initiative représente à la fois une expansion stratégique des affaires et une réponse à la demande des consommateurs pour des solutions de longévité basées sur la science.
Jupiter Neurosciences (NASDAQ: JUNS) hat eine strategische Partnerschaft mit Aquanova AG angekündigt, um Verbraucher-Nahrungsprodukte zu entwickeln, die sich auf Langlebigkeit, Alterung und Gesundheit konzentrieren. Die Zusammenarbeit baut auf ihrer 8-jährigen Partnerschaft zur Entwicklung von JOTROL™, der resveratrolbasierten Plattform von Jupiter, auf, die sich derzeit in der Phase IIa-Studie für die Parkinson-Krankheit befindet.
Die Unternehmen werden im Q3 2025 drei Verbraucherprodukte über ein Direct-to-Consumer-Modell einführen, das sich auf Konzepte von 'Schönheit von innen' konzentriert. Diese Produkte werden über eine neue, zu 100 % im Besitz von Jupiter befindliche Tochtergesellschaft vermarktet, wodurch bestehende Aktionäre an dem kommerziellen Unternehmen teilnehmen können, während Einnahmen zur Unterstützung laufender pharmazeutischer Studien generiert werden.
Die Partnerschaft nutzt die NovaSOL™-Technologie von Aquanova, um die Herausforderungen der Bioverfügbarkeit von Resveratrol anzugehen und eine effektive Absorption ohne gastrointestinale Nebenwirkungen sicherzustellen. Diese Initiative stellt sowohl eine strategische Geschäftserweiterung als auch eine Antwort auf die Verbraucheranforderungen nach wissenschaftlich fundierten Langlebigkeit-Lösungen dar.
- New revenue stream expected from consumer products launch in Q3 2025
- Strategic expansion into growing longevity market while maintaining pharmaceutical development
- Leveraging existing technology and partnership to create immediate commercial opportunities
- Revenue from consumer products will support ongoing pharmaceutical trials funding
- Consumer product launch delays pharmaceutical focus from core CNS drug development
- No immediate revenue impact until Q3 2025
- Potential resource division between pharmaceutical and consumer product development
Insights
Jupiter Neurosciences' partnership with Aquanova represents a strategic diversification for this micro-cap pharmaceutical company (
The planned Q3 2025 launch of three consumer products targeting the longevity market through a wholly-owned subsidiary offers several strategic advantages:
- Creates potential near-term revenue to support ongoing pharmaceutical trials without additional R&D investment
- Capitalizes on existing intellectual property and their 8-year collaboration
- Establishes market presence in the growing consumer healthspan sector
- Provides shareholders exposure to both pharmaceutical development and consumer health markets
This approach appears capital-efficient, as Jupiter can monetize their scientific platform through less-regulated consumer products while maintaining focus on their primary pharmaceutical pipeline. For a company at Jupiter's development stage, this represents an intelligent strategy to potentially extend cash runway without dilutive financing.
The Direct-to-Consumer model allows Jupiter to build brand recognition while avoiding the extensive marketing costs and competitive pressures of traditional retail channels. Creating a dedicated subsidiary structure also provides operational clarity and potential future optionality for this business segment.
First three consumer products expected to launch in Q3 2025, providing near-term revenue growth
Jupiter, Florida, March 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic partnership with Aquanova AG to jointly develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan.
“As we explore new ways to translate our scientific discoveries into tangible health solutions, we see an immense opportunity in the longevity and healthspan market,” said Christer Rosén, Chairman & CEO of Jupiter Neurosciences. “Aquanova has been an exceptional technology partner, and their expertise in formulation and execution will be instrumental in this venture. We believe that our pharmaceutical-driven approach and the strong clinical foundation behind JOTROL™ provide a unique advantage in delivering high-quality, effective products to consumers.”
Jupiter and Aquanova have collaborated for over eight years in the development of Jupiter’s lead product, JOTROL™, a proprietary resveratrol-based formulation currently advancing toward a Phase IIa trial in Parkinson’s Disease. Based on the extensive preclinical and clinical data supporting JOTROL™’s potential in central nervous system (CNS) disorders such as Alzheimer’s and Parkinson’s, the companies are now leveraging their combined expertise to expand into the rapidly growing longevity and healthspan market.
The jointly developed products will focus on the concept of “Beauty from Within,” emphasizing scientifically backed formulations designed to support longevity and overall health. The first three products are expected to launch in Q3 2025 through a Direct-to-Consumer (DTC) model, providing an immediate commercial pathway while Jupiter continues its clinical development efforts.
"We are incredibly proud of our partnership with Jupiter and look forward to the work they are doing to bring life-changing solutions for rare and difficult-to-treat diseases to market in the medicinal sphere and for superior supplement products targeting longevity and healthspan," said Frank Behnam, CEO of Aquanova. "Resveratrol is a powerful ingredient but it suffers from bioavailability and absorption challenges. Our NovaSOL™ technology ensures that resveratrol safely reaches effective levels in the body, without GI-side effects, creating reliable health solutions in many indications."
As part of this initiative, Jupiter plans to launch these products under a new wholly owned subsidiary, allowing existing shareholders to participate in the commercial success of the venture. This subsidiary is expected to generate revenue which will support Jupiter’s ongoing pharmaceutical trials.
“We frequently hear from individuals interested in accessing JOTROL™ immediately, particularly those with personal connections to neurodegenerative diseases,” Rosén added. “Like many, I have seen the devastating impact of Alzheimer’s and Parkinson’s firsthand. This initiative not only represents a strategic business expansion but also a meaningful step in addressing a growing consumer demand for science-backed solutions in aging and healthspan.”
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company’s platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company’s pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com.
About JOTROL
Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.
Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL toward a Phase IIa trial in Parkinson’s Disease.
About Aquanova & NovaSOL® Technology
Aquanova NA Corp. is the U.S. daughter company of Aquanova AG, headquartered in Germany, a leading phyto-technology manufacturer dedicated to enhancing the bioavailability of natural compounds. Founded in 1995, Aquanova AG offers scientifically proven health ingredients to customers worldwide. Utilizing its patented NovaSOL® technology, the company delivers micellized ingredients with superior efficacy and speed of absorption. www.aquanovacorp.com/ www.aquanova.de
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the Company’s ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
JUNS@redchip.com
FAQ
When will Jupiter Neurosciences (JUNS) launch its first consumer products with Aquanova?
What is the current development stage of JUNS's JOTROL platform for Parkinson's Disease?
How will the Aquanova partnership benefit JUNS shareholders?
What technology solution does the JUNS-Aquanova partnership use to improve resveratrol absorption?
